[Treatment with rituximab of autoimmune disease: results from AADEA's registry].
Callejas Rubio
José Luis
JL
Camps
María Teresa
MT
García-Hernández
Francisco
F
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001327:Autoimmune Diseases / Q000188:drug therapy*; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D009220:Myositis / Q000188:drug therapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy; D012042:Registries; D000069283:Rituximab; D013030:Spain; D013997:Time Factors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab